American Journal of Cancer Research,
Journal Year:
2024,
Volume and Issue:
14(12), P. 5965 - 5986
Published: Jan. 1, 2024
No
established
method
currently
exists
for
evaluating
tumor-infiltrating
lymphocytes
(TILs)
in
gastric
cancer
(GC),
and
their
clinical
significance
based
on
infiltration
site
GC
remains
unclear.
In
this
study,
we
developed
a
to
evaluate
TILs
according
as
prognostic
marker
GC.
We
retrospectively
analyzed
103
patients
with
advanced
who
underwent
curative
resection.
located
at
the
invasive
margin
(TIL
International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(6), P. 3563 - 3563
Published: March 21, 2024
Immunotherapies
have
revolutionized
cancer
treatment
approaches.
Because
not
all
patients
respond
positively
to
immune
therapeutic
agents,
it
represents
a
challenge
for
scientists
who
strive
understand
the
mechanisms
behind
such
resistance.
In-depth
exploration
of
tumor
biology,
using
novel
technologies
as
omics
science,
can
help
decode
role
microenvironment
(TIME)
in
producing
response
blockade
strategies.
It
also
identify
biomarkers
patient
stratification
and
personalized
treatment.
This
review
aims
explore
these
new
models
highlight
their
possible
pivotal
changing
clinical
practice.
Molecular Medicine,
Journal Year:
2025,
Volume and Issue:
31(1)
Published: Feb. 8, 2025
Abstract
Gastric
cancer
(GC)
is
one
of
the
most
common
malignant
tumors
worldwide,
and
its
treatment
has
been
a
focus
medical
research.
Herein
we
systematically
review
current
status
advancements
in
targeted
therapy
immunotherapy
for
GC,
which
have
emerged
as
important
strategies
recent
years
with
great
potential,
summarize
efficacy
safety
such
treatments.
Targeted
therapies
against
key
targets
including
epidermal
growth
factor
receptor
(EGFR),
human
2
(HER2),
vascular
endothelial
(VEGF)/VEGF
(VEGFR),
shown
remarkable
therapeutic
efficacies
by
inhibiting
tumor
progression
and/or
blood
supply.
In
particular,
markable
breakthroughs
made
HER2-targeting
drugs
HER2-positive
GC
patients.
To
address
intrinsic
acquired
resistances
to
drugs,
novel
agents
bispecific
antibodies
antibody–drug
conjugates
(ADC)
targeting
HER2
developed.
Immunotherapy
enhances
recognition
elimination
cells
activating
body
anticancer
immune
system.
Programmed
cell
death
protein
1
(PD-1)
programmed
death-ligand
(PD-L1)
are
commonly
used
immunotherapeutic
some
success
treatment.
Innovative
modalities,
adoptive
therapy,
vaccines,
non-specific
immunomodulators
oncolytic
viruses
promise
early-stage
clinical
trials
GC.
Clinical
supported
that
can
significantly
improve
survival
quality
life
However,
effects
need
be
further
improved
more
personalized,
advancement
researches
on
microenvironment.
Further
studies
remain
needed
issues
drug
resistance
adverse
events
pertaining
The
combined
application
individualized
should
explored
developed,
provide
effective
treatments
International Journal of Molecular Sciences,
Journal Year:
2025,
Volume and Issue:
26(4), P. 1557 - 1557
Published: Feb. 12, 2025
Gastric
cancer
(GC)
ranks
as
one
of
the
most
prevalent
malignant
tumors
globally.
The
subtle
manifestation
its
early-stage
symptoms
often
results
in
many
GC
patients
being
diagnosed
at
a
late
or
advanced
stage,
thereby
posing
significant
obstacles
to
effectiveness
chemotherapy
treatments.
Therefore,
identifying
early
biomarkers
for
is
crucial.
In
recent
years,
an
increasing
number
studies
have
highlighted
pivotal
role
that
aging
plays
progression
cancer.
Among
various
proteins
involved,
Cytoskeleton-associated
protein
2
(CKAP2)
emerges
crucial
player
controlling
cell
proliferation,
regulating
mitosis
and
division,
exerting
influence
on
process.
We
employed
bioinformatics
approach
assess
causal
association
between
aging-related
genes
explore
potential
significance
CKAP2
by
analyzing
data
sourced
from
repositories,
including
Genotype
Tissue
Expression
(GTEx),
GWAS
Catalog,
Database
Cell
Senescence
Genes
(CellAge),
Cancer
Genome
Atlas
(TCGA),
Gene
Omnibus
(GEO),
Human
Protein
(HPA),
Comparative
Toxicology
(CTD).
Our
research
summarized
relationship
expression
development
risk
GC,
differential
with
prognosis
genetic
correlation,
functional
analysis,
immune
infiltration,
explored
interaction
chemical
substances.
findings
revealed
elevation
correlated
reduced
likelihood
developing
GC.
There
was
difference
normal
patients.
Specifically,
there
higher
compared
addition,
has
been
proven
diagnostic
value
elevated
levels
are
indicative
more
favorable
prognosis.
Immune
infiltration
analysis
tumor
microenvironment,
while
(CTD)
identified
small
molecule
compound
may
target
CKAP2.
summary,
through
comprehensive
multivariate
analyses,
we
validated
play
shows
indicator
both
diagnosis
making
it
worthy
further
clinical
investigation.
CytoJournal,
Journal Year:
2025,
Volume and Issue:
22, P. 6 - 6
Published: Jan. 23, 2025
Objective:
Immune
response
is
crucial
in
the
development
of
gastric
cancer
(GC),
and
Jumonji
domain-containing
protein
6
(JMJD6)
plays
an
important
role
mediating
GC
cell
behavior.
This
study
aims
to
elucidate
mechanisms
through
which
JMJD6
affects
autophagy
immune
evasion
cells.
Material
Methods:
Immunocytochemistry
was
employed
assess
programmed
death-ligand
1
(PD-L1)
levels
line
(MKN-45)
epithelial
MKN-45
cells
with
knockdown
overexpression
were
generated.
The
effect
on
evaluated
using
counting
kit-8
assay,
cellular
fluorescence
staining,
Transwell
assays.
Western
blot
analysis
immunofluorescence
techniques
investigate
regulation
by
JMJD6.
Reactive
oxygen
species
(ROS)
applying
ROS
staining.
Meanwhile,
gene
expression
molecules
related
antioxidant
stress
responses
assessed
assays
quantitative
real-time
polymerase
chain
reactions,
respectively.
Results:
PD-L1
elevated
(
P
<
0.001).
enhanced
migration,
invasion,
colony
formation
vitro
In
cells,
epithelial-mesenchymal
transition
promoted
upregulation
but
notably
inhibited
increased
Sequestosome
1,
Microtubule-associated
1A/1B-light
3
(LC3)II/LC3I,
activation
further
addition,
reduced
production
response,
reverse
effects
observed
Conclusion:
facilitates
progression
modulating
oxidative
pathways.
Frontiers in Pharmacology,
Journal Year:
2025,
Volume and Issue:
16
Published: Feb. 13, 2025
The
process
of
drug
discovery
and
development
is
both
lengthy
intricate,
demanding
a
substantial
investment
time
financial
resources.
Bioinformatics
techniques
tools
can
not
only
accelerate
the
identification
targets
screening
refinement
candidates,
but
also
facilitate
characterization
side
effects
prediction
resistance.
High-throughput
data
from
genomics,
transcriptomics,
proteomics,
metabolomics
make
significant
contributions
to
mechanics-based
reuse.
This
paper
summarizes
bioinformatics
technologies
in
research
their
roles
applications
development,
aiming
provide
references
for
new
drugs
realization
precision
medicine.
Frontiers in Immunology,
Journal Year:
2025,
Volume and Issue:
16
Published: March 3, 2025
Gastric
cancer
(GC)
remains
a
significant
global
health
concern
due
to
its
poor
prognosis
and
limited
therapeutic
options,
particularly
in
advanced
stages.
Tumor
microenvironment
(TME),
tumor-associated
macrophages
(TAMs),
plays
key
role
tumor
progression,
immune
evasion,
therapy
resistance.
TAMs
exhibit
plasticity,
shifting
between
pro-inflammatory
M1
immunosuppressive
M2
phenotypes,
with
the
latter
predominating
GC
contributing
outcomes.
Recent
advancements
focus
on
targeting
TAMs,
including
inhibiting
polarization,
reprogramming
combining
TAM-targeted
approaches
checkpoint
inhibitors.
Innovations
nanotechnology,
metabolic
reprogramming,
pathways
such
as
interleukin-6
C-C
motif
ligand
2/C-C
chemokine
receptor
2
further
enhance
these
strategies.
However,
challenges
remain,
spatial
functional
heterogeneity
of
within
TME
need
for
selective
avoid
disrupting
homeostasis.
Ongoing
research
TAM
origins,
functions,
interactions
is
crucial
developing
precise
effective
therapies.
These
advances
hold
promise
not
only
improving
outcomes
but
also
addressing
other
cancers
similarly
complex
microenvironments.
